The Evidence Basis for the American College of Rheumatology Practice Guidelines
The American College of Rheumatology (ACR) places a high priority on developing methodologically rigorous, evidencebased Clinical Practice Guidelines (CPGs). 1 To assess the 
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Federally qualified health centers and calls in which appointment availability could not be confirmed (18.2% in 2012, 21.5% in 2014, and 22.1% in 2016) were excluded from the analyses. County-level weights were used on the basis of the portion of the population with each insurance type; weights were scaled so that states contributed equally to the 10-state mean. Standard errors were clustered at the state level.
evidential foundation of rheumatology guidelines, we evaluated (1) the level (quality) of the evidence base and (2) the class (strength or benefit to harm ratio) of the recommendations in the ACR CPGs.
Methods | As of March 10, 2017, we obtained 8 publically available CPGs (https://www.rheumatology.org) that assessed evidence using 3 different methodologies: American College of Cardiology/American Heart Association (ACC/AHA) approach in 3, Grading of Recommendations and Assessment, Development, and Evaluation scoring system (GRADE) in 4, and University of Oxford Centre for Evidence-Based Medicine approach in one. To compare the guidelines using an identical methodology, we classified the level (quality) of evidence and class (strength) of the recommendations using the ACC/AHA method.
Working independently, 2 reviewers (A.D. and R.Z.) extracted the reported evidence level and class for each recommendation. When recommendations involved multiple population, intervention, comparator and outcome (PICO) questions, we weighted their contribution to the recommendation equally (eg, each of 4 PICO questions contributed onefourth of the evidence). Occasionally, consensus involved assigning a recommendation to 2 categories (ie, contributing 0.5 to each). We summarized the distribution of recommendations by level and class using medians and interquartile range to weigh each guideline equally.
Results | Glucocorticoid-induced osteoporosis (GIOP), juvenile idiopathic arthritis (JIA), gout, lupus nephritis, osteoarthritis (OA), ankylosing spondylitis (SpA), polymyalgia rheumatica (PMR), and rheumatoid arthritis (RA) comprised the 8 guidelines, which involved 403 (ranging from 10 to 102 each) recommendations.
Four guidelines (OA, SpA, PMR, and RA) reported class and level in their 143 recommendations, and 4 (GIOP, JIA, gout, and lupus nephritis) reported only evidence level. Across guidelines (Table 1) , over half of the 403 recommendations were classified as level C, one-fourth (93 recommendations) level A, and one-fifth (77 recommendations) level B. The proportion of level A varied from 58% with OA and 35% with GIOP to 2% with JIA and 10% with PMR. Abbreviations: GRADE, Grading of Recommendations and Assessment, Development, and Evaluation scoring system; IQR, interquartile range; OA, osteoarthritis; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis; SpA, spondyloarthritis. a Class I strength of recommendation was assigned when a given procedure or treatment should be performed or administered (benefit much greater than harm); class II when a procedure or treatment is reasonable or may be considered (benefit greater than or equal to harm); and class III when procedure or treatment is not effective or useful and may be harmful (harm or no benefit). Table 2 examines the relationship between the level of evidence and class of the recommendations. A median of 10% specified both level of evidence A and class I; 6%, level B and class I, and 8% level C and class I. The RA guideline had the highest percentage (16%) of such strong class I recommendations based on weak C evidence. The combination class II and level C evidence was the most common at a median of 30% across guidelines and comprised 50% of the RA recommendations.
Discussion | Our findings suggest the evidence supporting ACR recommendations is limited, with more than 50% and occasionally 2 of every 3 recommendations classified as level C, that is, based on experts, standards of care, case reports or series. Of the 35 class I recommendations, only 17 were supported by level A evidence. Our analysis reflects the different methodologies used in the ACR guidelines at 1 time point. Most recently, the ACR applies GRADE to evaluate the study design and the quality of the evidence. 2 The ACR recommendations overall remain mostly expert-based but are comparable with guidelines in other subspecialties. [3] [4] [5] The findings underline the need to enhance the evidence level. Although RCT evidence level A for all clinical questions is infeasible, in this era of "big data," the creation of registries, (eg, ACR's RISE 6 and federal real-world data initiatives) should increase opportunities to build a learning health care system. Such a system would identify heterogeneity and gaps in care practices and outcomes, which would help set research priorities that would enhance the quality of rheumatology care and increase appropriate use and patient-centered clinical outcomes while minimizing unwarranted practice variation.
Association Between Physicians' Experiences With Members of Their Social Network and Efforts to Reduce Breast Cancer Screening
Physician recommendations strongly influence women's decisions to receive breast cancer screening, 1 but current evidence suggests physician adherence to evolving guidelines that recommend less screening is suboptimal. 2, 3 Clinical encounters and experiences with friends, colleagues, and family members who have been diagnosed with breast cancer may affect physician screening recommendations. These personal and professional experiences may provide physicians with anecdotal information about breast cancer screening fundamentally different from-and potentially at odds with-scientific evidence that relies on estimates of mortality reduction. 4 With information from a national survey of gynecologists and primary care physicians, we investigated whether physician experiences with patients, friends, colleagues, and family members diagnosed with breast cancer were associated with their recommendations for breast cancer screening.
Methods | The Breast Cancer Social Networks study (CanSNET) is a national mailed survey fielded from May 2016 to September 2016 that included 2000 primary care physicians randomly selected from the American Medical Association Masterfile. 3 Participants included gynecologists and internal medicine, family medicine, and general practice physicians who were surveyed about their breast cancer screening practices. Approval for this study was obtained from and signed patient consent was waived by the institutional review board at Johns Hopkins University School of Medicine.
